nuv-1182

NUV-1182 is a potent, selective small molecule **adenosine A2A receptor antagonist**[3][7][1]. It was designed to inhibit the A2A adenosine receptor with high affinity (single-digit nanomolar binding), aiming to boost immune function and enhance the efficacy of immuno-oncology (IO) therapies by overcoming tumor-induced immunosuppression[1][3][7][11]. Developed primarily for oncology, preclinical data suggested the drug could increase the effectiveness of checkpoint inhibitors as part of combination therapy strategies[12]. NUV-1182 was developed by Nuvation Bio as part of a pipeline to address significant unmet needs in cancer treatment, but the program was deprioritized and clinical development has been discontinued[5][12].

Brand names

NUV-1182NUV1182NUV 1182

Other names

NUV-1182NUV1182NUV 1182